Clinical TrialJul 17, 2026, 06:56 AM
GSK Halts Camlipixant Development for Chronic Cough
AI Summary
GSK announced an update on its Phase III CALM-1 and CALM-2 trials for camlipixant in refractory chronic cough (RCC). While CALM-1 met its primary endpoint for the 50mg dose, CALM-2 did not achieve statistical significance, and the 25mg dose failed in both studies. Due to limited efficacy and the unlikelihood of transforming patient care, GSK has decided to discontinue further development of camlipixant for RCC. However, the Phase IIb BALANCE trial for camlipixant in irritable bowel syndrome (IBS-D and IBS-M) will continue.
Key Highlights
- CALM-1 Phase III trial met primary endpoint for camlipixant 50mg twice daily in refractory chronic cough.
- CALM-2 Phase III trial did not meet primary endpoint for camlipixant 50mg twice daily.
- Camlipixant 25mg twice daily did not achieve statistical significance in either CALM study.
- Key secondary endpoints did not meet target thresholds in both CALM-1 and CALM-2 trials.
- GSK will not progress further development of camlipixant for refractory chronic cough.
- Phase IIb BALANCE trial for camlipixant in IBS-D and IBS-M will continue.
Price Impact
More from GSK
More in Clinical Trial